Mizuho Forecasts Strong Price Appreciation for Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics (NASDAQ:AVTX) had its target price boosted by Mizuho from $39.00 to $45.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Mizuho’s price target would indicate a potential upside of 126.70% from the stock’s current price.

A number of other equities analysts also recently issued reports on the company. Guggenheim initiated coverage on Avalo Therapeutics in a research report on Monday, February 2nd. They set a “buy” rating and a $50.00 price target on the stock. Citigroup reaffirmed an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th. Wolfe Research initiated coverage on Avalo Therapeutics in a research report on Thursday, April 9th. They set an “outperform” rating and a $48.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Wednesday, April 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $60.00 price target (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday. Eleven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.75.

Avalo Therapeutics Trading Down 0.5%

Shares of AVTX stock opened at $19.85 on Thursday. The business’s fifty day simple moving average is $15.84 and its 200-day simple moving average is $16.44. The company has a market cap of $582.20 million, a PE ratio of -3.46 and a beta of 0.78. Avalo Therapeutics has a 12-month low of $3.39 and a 12-month high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.02. On average, equities analysts forecast that Avalo Therapeutics will post -3.1 earnings per share for the current year.

Insider Activity

In other news, insider Paul Varki sold 75,063 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the sale, the insider directly owned 3,634 shares of the company’s stock, valued at $73,297.78. The trade was a 95.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Ryan Sullivan sold 8,457 shares of the company’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $13.23, for a total transaction of $111,886.11. Following the completion of the sale, the chief financial officer directly owned 423 shares in the company, valued at approximately $5,596.29. The trade was a 95.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 138,078 shares of company stock valued at $2,501,346 over the last ninety days. 4.46% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Avalo Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Orbimed Advisors LLC boosted its holdings in Avalo Therapeutics by 39.5% in the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock valued at $17,150,000 after purchasing an additional 382,300 shares during the last quarter. Nantahala Capital Management LLC boosted its holdings in Avalo Therapeutics by 24.1% in the third quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock valued at $15,697,000 after purchasing an additional 240,000 shares during the last quarter. Affinity Asset Advisors LLC boosted its holdings in Avalo Therapeutics by 4.5% in the fourth quarter. Affinity Asset Advisors LLC now owns 1,051,054 shares of the company’s stock valued at $19,087,000 after purchasing an additional 44,837 shares during the last quarter. Caligan Partners LP boosted its stake in shares of Avalo Therapeutics by 5.8% during the 4th quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock worth $16,009,000 after acquiring an additional 48,200 shares in the last quarter. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of Avalo Therapeutics during the 3rd quarter worth about $10,390,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.